EZR and breast carcinoma: As CD44 promotes breast cancer malignancy by interacting with cytoskeleton linker proteins, such as Ezrin, thus triggering the PI3K-related survival pathway26–28, we next determined the role of Ezrin in CD44/HA induced resistance.